GET DAILY SIGNALSWhy Is SciSparc Ltd. (SPRC) Stock Down -37.21% Today?
Key Takeaways
- SPRC shares plunged roughly 37.2% to about $0.81, reversing a sharp rally from the prior session's close of $1.29.
- The primary catalyst was profit-taking and a violent unwinding of the speculative, AI-driven surge that followed the company's recent "Agentic AI" pivot announcement.
- Dilution risk is a key secondary driver: a $2 million convertible note is being converted into shares at $1.50, threatening to materially increase the share count.
- The stock is a micro-cap with roughly $856,000 in annual revenue and negative earnings, leaving it vulnerable to outsized volatility.
- Traders are watching upcoming earnings, clinical-trial enrollment progress, and whether management delivers substance behind the AI strategy.
- For more detail on valuation and expectations, explore Price Targets, Earnings, and Forecast pages for this ticker.
- To see how AI-powered strategies are navigating volatile names like this one, visit Trending AI Robots.
Opening Summary
SciSparc Ltd. (SPRC), a Tel Aviv-based clinical-stage pharmaceutical company developing cannabinoid-based therapies and, more recently, repositioning itself around agentic AI technologies, suffered a steep sell-off in Tuesday's session. The stock tumbled approximately 37.2% to trade near $0.81, down from the prior completed session's closing price of $1.29. The decline marked a decisive reversal of the previous day's 18% surge and reflected a market reassessing a speculative AI-themed rally against persistent dilution and fundamental concerns.
Reversal of the Agentic AI Rally
The sharpest driver of the move was the unwinding of momentum built around the company's October 15 announcement that it would shift its strategic focus toward "Agentic AI" technologies in cybersecurity and finance. The headline initially ignited a buying frenzy, with shares spiking on enormous volume. However, the announcement named no product, no contract, and no revenue stream, and the company itself cautioned that there was "no assurance" the effort would produce any transaction or revenue-generating activity.
With the underlying business offering only minimal revenue and the AI pivot lacking concrete deliverables, the enthusiasm proved fragile. Tuesday's selling reflected traders locking in gains and stepping away from a narrative-driven rally that lacked fundamental support, a classic pattern in thinly traded micro-cap names.
Dilution and Capital-Raise Concerns
Compounding the downside pressure, investors weighed the impact of convertible financing. On the same day the AI pivot was unveiled, the company disclosed that a $2 million debt instrument was being converted into ordinary shares at $1.50. Because the share count was already tiny following a 1-for-9 reverse split earlier in the year, the conversion has the potential to meaningfully expand the outstanding share base and dilute existing holders.
For a company of this size, the prospect of substantial dilution tends to weigh heavily on sentiment, particularly when the share price has run up on speculation. The market reaction suggested that concerns about share-count expansion outweighed the appeal of the AI rebranding.
Market Context and Trading Activity
Trading activity underscored the stock's volatility. The prior session saw volume spike to roughly 12.9 million shares, many times the stock's typical average of around 1.4 million, as momentum traders piled in. Tuesday's decline followed on comparably heavy turnover, indicating that the move was driven by active repositioning rather than a slow drift lower.
The sell-off was idiosyncratic rather than sector-driven. Broader healthcare and biotechnology benchmarks did not exhibit a comparable collapse, suggesting the decline stemmed from company-specific dynamics — namely the reversal of a speculative catalyst and dilution concerns — rather than any broad market or macro shock. The stock's low float and minimal market capitalization amplify percentage swings in either direction.
What Comes Next for SPRC
Looking ahead, investors will be watching several developments. The company's next earnings report is anticipated in mid-to-late November, providing a fresh read on its financial position and cash runway. On the clinical front, progress on SCI-110 for Tourette syndrome and Alzheimer's-related agitation, as well as SCI-210 for autism spectrum disorder, remains central to the underlying pharmaceutical narrative.
The bigger question is whether management can translate the agentic AI strategy into tangible products, partnerships, or revenue. Until then, the stock is likely to remain highly sensitive to headlines and financing activity. Risks include further share issuance, the uncertain path of early-stage clinical programs, and the inherent volatility of a micro-cap with limited liquidity and thin analyst coverage.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to observe how data-driven systems approach fast-moving and volatile names. Explore the section to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SPRC in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026
SPRC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 36 cases where SPRC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRC as a result. In 85 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRC turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SPRC entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.958) is normal, around the industry mean (3.037). P/E Ratio (0.000) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement